Last $672.60 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:09 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Open
$680.00
Previous Close
$672.60
Day High
$680.00
Day Low
$672.60
52 Week High
05/5/14 - $710.59
52 Week Low
02/6/14 - $626.75
Market Cap
1.8T
Average Volume 10 Days
298.5
EPS TTM
--
Shares Outstanding
2.6B
EX-Date
05/7/14
P/E TM
--
Dividend
$1.89
Dividend Yield
3.69%
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., and Medtronic, Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi-adr (SNYN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi-adr (SNYN) Key Developments

Blackstone Reportedly Among Potential Bidders For Drugs Of Sanofi

The Blackstone Group L.P. (NYSE:BX) are reportedly among the potential bidders for the portfolio of mature drugs of Sanofi (ENXTPA:SAN). The transaction is reported to be valued at approximately €6.3 million.

Sanofi Reportedly In Talks With Buyers For Sale Of Drug Portfolio

Sanofi (ENXTPA:SAN) has held talks with Abbott Laboratories (NYSE:ABT), Mylan, Inc. (NasdaqGS:MYL) and private equity firms for the possible sale of a €6.3 billion portfolio of mature drugs, according to an internal document seen by Reuters.

Sanofi and Regeneron Pharmaceuticals Announce Results from Phase 2B Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced positive results from a phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared to placebo. Dupilumab is an investigational monoclonal antibody that blocks signaling of IL-4 and IL-13, two cytokines that play a key role in the pathogenesis of moderate-to-severe atopic dermatitis. In the phase 2b trial, all five subcutaneous doses of dupilumab showed a dose-dependent improvement in the primary endpoint, the mean percentage change in EASI score from baseline to week 16. The improvements in EASI score ranged from a high of 74% for patients in the higher dose group, who received 300 milligrams (mg) weekly, to a low of 45% in patients who received the lowest dose of 100 mg monthly, compared to 18% for patients in the placebo group (p<0.0001 for all doses). The most common adverse event in the phase 2b study was nasopharyngitis, which was balanced across dupilumab treatment groups (18.5% to 23%) compared to placebo (21%). Injection site reactions were more frequent in the dupilumab group (5% to 9.5%) compared to placebo (3%), as was headache (12% to 15%) compared to placebo (8%). Dupilumab-treated patients showed highly statistically significant and dose-dependent improvements in additional key efficacy measures compared to placebo after 16 weeks of treatment: 12% to 33% of dupilumab-treated patients achieved clearing or near-clearing of skin lesions, as measured by an investigator's global assessment (IGA) score of 0% or 1%, compared to 2% with placebo. (p=0.02 to p<0.0001). Dupilumab-treated patients experienced a 16.5% to 47% mean reduction in itching, as measured by the pruritus numerical-rating scale (NRS) score, compared to an increase of 5% in the placebo group. (p=0.0005 to p<0.0001). This phase 2b double-blind, placebo-controlled, 16-week, dose-ranging study randomized 380 patients with moderate-to-severe atopic dermatitis, who could not be adequately controlled with topical medication or for whom topical treatment was not advisable. Patients were randomized to receive one of five doses of dupilumab (300 mg weekly, 300 mg every other week, 300 mg monthly, 200 mg every other week, 100 mg monthly) or placebo. Patients in the study had approximately 50% of their skin affected by atopic dermatitis at baseline. Within the past year, approximately 35% of patients received an oral corticosteroid and approximately 20% received a systemic immunosuppressant for AD. Approximately 60% of patients had another allergic condition, including approximately 40% of patients who had a history of asthma. The follow-up period of the study is ongoing and patients will be followed for 16 weeks after treatment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $672.60 MXN 0.00

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €101.16 EUR +1.81
Gilead Sciences Inc $93.61 USD +0.62
GlaxoSmithKline PLC 1,425 GBp +6.00
Merck & Co Inc $58.03 USD -0.55
Novo Nordisk A/S kr257.50 DKK +1.00
View Industry Companies
 

Industry Analysis

SNYN

Industry Average

Valuation SNYN Industry Range
Price/Earnings 26.3x
Price/Sales 3.0x
Price/Book 1.7x
Price/Cash Flow 14.9x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.